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DC-SIGN: A Guide to Some Mysteries Minireview
of Dendritic Cells
entry into the DC. Therefore, DC-SIGN likely will be piv-
otal for explaining some important functions of DCs.
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The term ªpotencyº indicates that relatively small num-
bers of DCs, and relatively low doses of an antigen or
other T cell stimulus, are sufficient to initiate rapid andDuring the last decade, dendritic cells (DCs) have come
strong responses, such as T cell proliferation and lym-to be appreciated as critical controllers of the immune
phokine production. Potency is not simply a matter ofresponse, especially T cell responses. Although T lym-
more efficient MHC±peptide complex formation, al-phocytes actually mediate resistance to infections,
though this too is a newly recognized mechanism usedtransplants, and even tumors, without proper instruction
by DCs to control immunity (Inaba et al., 2000). Insteadfrom DCs, T cells would be severely compromised. DCs
potency is readily observed with stimuli that do not re-convert antigens from foreign cells and infectious micro-
quire processing, e.g., polyclonal mitogens, microbialorganisms into short peptides that are bound to mem-
superantigens, and transplantation antigens. DCs arebrane proteins of the major histocompatibility complex
also effective when the amount of membrane-bound(MHC). These MHC±peptide complexes are formed in-
TCR ligand is vanishingly small, as few as 100±1000tracellularly but are ultimately presented on the plasma
ligands on the entire cell surface (Bhardwaj et al., 1993).membrane where they serve as ligands for antigen-spe-
For these reasons, the efficacy of DCs has been attrib-cific T cell receptors (TCR). In addition to TCR ligand
uted to special accessory molecules. Many such mole-formation, DCs carry out many other functions, some
cules are found on DCs, e.g., CD48, -54, -58, -80, -86,to be considered below, which allow them to control
and the corresponding antibodies can block DC±T cellimmunity at several points.
interactions. However, these membrane proteins areDespite their importance, the DC can be regarded as
shared with other antigen-presenting cells. DC-SIGN isthe Cinderella of the immune system, for years kept by
the first recognized DC-restricted product that helpsthe hearths of a few laboratories. With added attention,
stimulate resting T cells.as illustrated by two papers by Geijtenbeek and col-
The Figdor lab realized that resting T cells expressedleagues in this issue of Cell, one can begin to appreciate
the adhesion molecule ICAM-3. In contrast to what wassome of the DC's glamor. Both papers center on DC-
expected, ICAM-3 did not bind to b2 integrins on DCs.SIGN, a new DC-restricted molecule. DC-SIGN in turn
When they made antibodies to block ICAM-3 binding toqualifies as Cinderella's glass slipper, as it seems to be
DCs, the monoclonals identified a small 44 kDa mole-used by the dashing T cell and the wicked HIV-1 to
cule. Its binding to ICAM-3 was Ca21 dependent andidentify their DC. Yet the slipper, like its wearer, had to
blocked by mannan. The antibodies reacted specificallybe rescued from years of oblivion. None of the new
with DCs. Cloning showed that the ICAM-3-binding mol-ideas described in the papers by Geijtenbeek et al. were
ecule was identical to the previously defined HIV-1 enve-apparent from the genomic sequence of DC-SIGN, first
lope±binding lectin (Curtis et al., 1992). In functionalreported in 1992 and since then deposited several times
tests, the renamed DC-SIGN contributed to transientin gene banks. Instead the research had to shift to DCs
DC±T cell clustering and responses to transplantation
for the importance of this molecule to be appreciated.
antigens.
DC SIGN is a type II membrane protein with an external
Geijtenbeek et al. (2000a) propose that DC-SIGN me-
mannose-binding, C-type lectin domain. It was cloned diates the known loose adhesion that takes place be-
from a placental library, through its capacity to bind the tween DCs and T cells in the apparent absence of foreign
glycan-rich HIV-1 envelope in the absence of CD4 (Curtis antigen (Figure 1). Such adhesion seems necessary,
et al., 1992), the classic virus receptor. In the first of because MHC±peptide ligands are membrane bound,
these two papers (Geijtenbeek et al., 2000a), the lectin typically scarce (10±1000 copies/cell), and need to be
is rediscovered and renamed DC-SIGN, because it is a recognized by the TCR, another membrane molecule.
ªDC-specific, ICAM-3 grabbing, nonintegrin.º It is pro- DC-SIGN-mediated adhesion provides an opportunity
posed that the interaction of DC-SIGN with ICAM-3 es- for the TCR to scan the DC surface to identify these
tablishes the initial contact of the DC with a resting T cell, small amounts of TCR ligand, which then activate the
helping to explain the potency with which DCs initiate T resting T cell. Subsequently T cells respond vigorously
cell immunity. Potency has long been apparent in tissue to antigens presented by other cells, but by then, the
culture and in experimental animals, and this adjuvant activated T cells are replete with their own functional
role of DCs has been extended to humans (Dhodapkar adhesion molecules.
and Bhardwaj, 2000). The second paper (Geijtenbeek et Further experiments will decipher this proposed
al., 2000b) addresses the known capacity of DCs to mechanism of action and dissect DC-SIGN function in
promote HIV-1 infection in culture. DC-SIGN proves to vivo. Mice deleted of the gene for DC-SIGN will be valu-
be a special kind of viral receptor, promoting binding able, assuming there are no additional homologs. Never-
and transmission of HIV-1 to T cells, rather than viral theless, it is impressive at this early stage of research
to recall that human cells have been used to uncover
most of the important accessory membrane proteins*E-mail: steinma@rockvax.rockefeller.edu.
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Figure 1. A Proposed Sequence of Action for the Initiation of Immunity by DCs
that control T cell function, not just DC-SIGN and ICAM-3. or -86 plus CD28, and importantly, MHC±peptide plus
TCR (Figure 1). This assembly of supramolecular aggre-These include CD58 (LFA-3) for CD2; CD54 (ICAM-1) for
CD11a (LFA-1); CD40L (gp39) for CD40; CD80 (B7-1) and gates may facilitate costimulation and sustain the low
affinity interaction between TCR ligands and the TCR.CD86 (B7-2) for CD28 and CD154 (CTLA-4) (Figure 1).
Geijtenbeek et al. (2000a) detected DC-SIGN on DCs Direct experiments on synapses have so far used acti-
vated T cells. DCs might allow the concept to be pursuedthat were not mature or terminally differentiated, and
expression of DC-SIGN did not increase when the DCs in naive T cells. In sum, more precise mechanisms are
beginning to explain DC function: DC-SIGN for T cellmatured. This raises the possibility that DC-SIGN is
mainly needed by developing DCs, not yet expressing adhesion, and preformed aggregates of MHC±peptide
and membrane accessories for costimulation.optimal levels of MHC±peptide and accessory mole-
cules like CD86, to contact ICAM-3 on resting T cells We have only been discussing the basis for DC po-
tency in vitro. In vivo, DCs are found in peripheral tissues,and then mature with help from the responding T cells.
Conceivably, DC-SIGN could be involved in T cell re- such as the skin and airways but they can migrate to
lymphoid tissues. There, in the T cell areas, the DCs aresponses other than classical immunity, such as the in-
duction of tolerance and immune regulation. in full view of the circulating, naive lymphocyte repertoire
and can even make chemokines that attract these TAlthough DC-SIGN could be a long-sought, DC-
unique molecule for T cell adhesion, and thereby help cells (Adema et al., 1997). The match of the DC and T
cell can then be made via DC-SIGN, allowing the intimateto explain the potency of DCs, there has been progress
on another hypothesis. DCs are held to have other cross-talk between the two cells to begin (Ingulli et al.,
1997). Nonetheless, to control immunity, the DC displaysunique products to enhance signaling together with the
TCR, i.e., costimulation. While DCs are remarkable in other functions prior to the use of DC-SIGN. In the pe-
ripheral outposts for antigen entry, DCs are immaturethis regard, to date costimulation is not known to involve
a DC-specific product. Instead, the potent costimulator, requiring a stimulus, such as exposure to microbial
products or inflammatory cytokines, for terminal differ-CD86, is abundant on DCs relative to other antigen-
presenting cells. More remarkably, during the vesicular entiation (Cella et al., 1997). The immature DCs express
several receptors for antigen uptake, including othertransport of newly formed MHC±peptide complexes in
developing DCs, the complexes move together with lectins (Figure 1, top). The endocytic system is in turn
regulated by a maturation stimulus to efficiently convertCD86. Upon arrival at the DC surface, MHC±peptide
and CD86 are deposited as stable clusters (Inaba et antigens to MHC±peptide complexes, in concert with
CD86 costimulators as mentioned above (Inaba et al.,al., 2000). Therefore DCs are designed to set up the
ªimmunological synapse.º 2000). DC migration from the periphery to the lymphoid
tissues involves mobilization via multidrug resistanceThe concept of a synapse, a term first coined by Wil-
liam Paul, proposes a central contact zone in which the receptors (Randolph et al., 1998) and chemotaxis through
the CCR7 receptor toward chemokines produced inAPC and T cell membranes are only 134 AÊ apart (Davis
and van der Merwe, 1996; Shaw and Dustin, 1997). The lymphoid tissues and lymphatic channels (Forster et al.,
1999). After DC-SIGN functions, the synapse forms andzone contains multiple copies of molecular couples that
span this distance, e.g., CD48 or -58 plus CD2, CD80 the resting T cell is activated. Then TNF family members
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Figure 2. Proposed Pathways for the Trans-
mission of HIV-1 or SIV to Permissive T Cells
The upper, DC-SIGN-dependent pathway
does not distinguish M-tropic from T-tropic
HIV-1. It may operate, for example, on DCs
beneath mucosal epithelial surfaces and is
the major pathway in the cells studied by Geij-
tenbeek et al. (2000b). The lower, infection-
dependent pathway may pertain to DCs
within mucosal epithelia. Both pathways also
could operate in acute and chronic phases
of infection in lymphoid tissues.
on the T cell, like CD40L and TRANCE, prolong DC sur- It is possible that other pathogens are also transmitted
via DCs and in particular via DC-SIGN. The glycan li-vival and cytokine production (Josien et al., 2000), espe-
gands for this lectin could be present on other viralcially the IL-12 needed for strong T cell±mediated immu-
envelopes, the cell walls of other microbes, or evennity (Figure 1). Therefore DC potency is not due to one
tumor cells. Also, because DC-SIGN retains its HIV-1surface or secreted molecule. It results from many well-
ligand in a native state, this and other lectins couldtimed and spatially organized specializations.
present vaccines to protective B cells, which must reactDCs and the Transmission of HIV-1
to native antigens. If the vaccine were simultaneouslyThe second of the two papers (Geijtenbeek et al., 2000b)
processed and presented to helper T cells, DC-SIGNreveals a new way for HIV-1 to exploit the DC. The
would even set up an effective DC±T±B ªmeÂ nage aÁ trois,ºinvestigators describe a fascinating DC-SIGN-depen-
capable of inducing strong immunity, including mucosaldent mechanism. This lectin can capture HIV-1 at low
immunity (Fayette et al., 1997).external titres. Without allowing viral entry, DC-SIGN
DC-SIGN is not the only attraction that HIV-1 finds inretains the attached virus in an infectious state for days
DCs. The virus can infect certain DCs in culture (Figureand then transmits it to replication-permissive T cells.
2, bottom, red arrows). HIV-1 is capable of replicationThe in vitro data are fortified with micrographs of tissue
in immature DCs, and possibly mature DCs that aresections. DC-SIGN is found on dendritic profiles be-
interacting with CD40L or T cells (Granelli-Piperno etneath genital epithelium, a major potential site for HIV-1
al., 1999). So while DC-SIGN can transport HIV-1 andtransmission, and in the T cell areas, the sites for viral
enhance infection of T cells, locally or in lymphoid tis-replication especially in acute infection. This pure deliv-
sues, direct infection could also amplify the amount ofery role for DC-SIGN is consistent with data that, in
virus that DCs deliver. Both pathways (Figure 2) maylymphoid tissues, HIV-1 and SIV mainly replicate in CD41
enhance the overall pathogenesis of HIV-1 infection,
T cells, not DCs (Stahl-Hennig et al., 1999).
although Geijtenbeek et al. (2000b) observe that DC-
The new experiments use a standard system to study SIGN in their cells plays the major role in viral replication,
the involvement of DCs in HIV-1 transmission (Pope et especially at low doses of HIV-1.
al., 1994). The model is to add HIV-1 to cultured DCs Importantly, it is well established that M-tropic strains
for 1±2 hr, wash, and at varying times, add in T cells of HIV-1 are preferentially transmitted among humans.
and follow the levels and cellular sites of viral replication. One possible explanation is that selection takes place
A vigorous infection occurs, primarily in T cells. In such at the level of DC infection. By contrast, DC-SIGN ferries
a model, antibodies to DC-SIGN exerted a significant both M- and T-tropic viruses to T cells. Geijtenbeek et
but sometimes incomplete block of transmission. When al. (2000b) did not detect DC-SIGN on DCs (Langerhans
transfected cells were used to pursue the relative roles cells) within the genital epithelium, only on DCs beneath
of DC-SIGN and more classical HIV-1 receptors, DC- the surface. These two subsets of DCs, termed ªepider-
SIGN was not an entry receptor and did not influence mal or epithelialº and ªdermal or subepithelial,º repre-
the entry role of CD4 and CCR5. However, DC-SIGN on sent distinct pathways of differentiation (Caux et al.,
one transfectant captured virus, even when present in 1996). Since epidermal, DC-SIGN-negative DCs likely
small amounts, and transmitted the HIV-1 to CD4 and select for M-tropic HIV-1 (Reece et al., 1998), these DCs
CCR5 on other cells (Figure 2, top). DC-SIGN literally in vivo may account for the selective transmission of
ªpresentsº HIV-1 to T cells, but in a nonprocessed infec- M-tropic HIV-1, which then binds to additional subepithe-
lial, DC-SIGN-positive DCs, greatly amplifying deliverytious form.
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Inaba, K., Turley, S., Iyoda, T., Yamaide, F., Shimoyama, S., Reis eof virus to T cells locally and eventually lymphoid tissue.
Sousa, C., Germain, R.N., Mellman, I., and Steinman, R.M. (2000).Beyond these functions in HIV-1 capture and convey-
J. Exp. Med., in press.ance, DCs can serve another nefarious role, activating
Ingulli, E., Mondino, A., Khoruts, A., and Jenkins, M.K. (1997). J.T cells to be permissive for HIV-1 replication (Figure 2,
Exp. Med. 185, 2133±2141.
right).
Josien, R., Hi, H.-L., Ingulli, E., Sarma, S., Wong, B.R., Vologodskaia,Implications M., Steinman, R.M., and Choi, Y. (2000). J. Exp. Med. 191, 495±501.
A new DC-restricted molecule, DC-SIGN, demystifies
Pope, M., Betjes, M.G.H., Romani, N., Hirmand, H., Cameron, P.U.,
two of this cell's contrasting functions: stimulating T Hoffman, L., Gezelter, S., Schuler, G., and Steinman, R.M. (1994).
lymphocytes to develop immunity, and enhancing HIV-1 Cell 78, 389±398.
and SIV replication. For immunity, it is implied that DC- Randolph, G.J., Beaulieu, S., Pope, M., Sugawara, I., Hoffman, L.,
SIGN allows the DC to interact temporarily with naive T Steinman, R., and Muller, W.A. (1998). Proc. Natl. Acad. Sci. USA
95, 6924±6929.cells. Critical events of antigen recognition can then
Reece, J.C., Handley, A., Anstee, J., Morrison, W., Crowe, S.M., andensue, leading to the formation and function of a contact
Cameron, P.U. (1998). J. Exp. Med. 187, 1623±1631.zone termed the immunological synapse, rich in inter-
Shaw, A.S., and Dustin, M.L. (1997). Immunity 6, 361±369.acting adhesion and signaling molecules. For immuno-
Stahl-Hennig, C., Steinman, R.M., Tenner-Racz, K., Pope, M., Stolte,deficiency viruses, DC-SIGN enables the DC to bind and
N., Matz-Rensing, K., Grobschupff, G., Raschdorff, B., Hunsmann,transmit virus to permissive T cells. This should occur
G., and Racz, P. (1999). Science 285, 1261±1265.in vivo beneath the genital epithelium and in the T cell
areas of lymphoid tissues, because of DC-SIGN expres-
sion in these sites. DC-SIGN may allow DCs to carry
additional pathogens to their cellular targets. The new
data identify DC-SIGN as a potential site on DCs for
manipulating both the immune response and HIV-1 in-
fection. The results illustrate a larger issue. To under-
stand and manipulate immune responsiveness, and
many clinical areas involving the immune system, one
should not restrict the analysis to antigens and lympho-
cytes. One must also consider DCs, the captivating con-
trollers of immunity.
Acknowledgments
The author regrets that, because of space limitations, many valuable
references could not be included.
Selected Reading
Adema, G.J., Hartgers, F., Verstraten, R., de Vries, E., Marland, G.,
Menon, S., Foster, J., Xu, Y., Nooyen, P., McClanahan, T., Bacon,
K.B., and Figdor, C.G. (1997). Nature 387, 713±717.
Bhardwaj, N., Young, J.W., Nisanian, A.J., Baggers, J., and
Steinman, R.M. (1993). J. Exp. Med. 178, 633±642.
Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-Dambuyant, C.,
de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D.,
and Banchereau, J. (1996). J. Exp. Med. 184, 695±706.
Cella, M., Sallusto, F., and Lanzavecchia, A. (1997). Curr. Opin. Im-
munol. 9, 10±16.
Curtis, B.M., Scharnowske, S., and Watson, A.J. (1992). Proc. Natl.
Acad. Sci. USA 89, 8356±8360.
Davis, S.J., and van der Merwe, P.A. (1996). Immunol. Today 17,
177±187.
Dhodapkar, M.V., and Bhardwaj, N. (2000). J. Clin. Immunol., in press.
Fayette, J., Dubois, B., Vandenabelle, S., Bridon, J.-M., Vanbervliet,
B., Durand, I., Banchereau, J., Caux, C., and Briere, F. (1997). J.
Exp. Med. 185, 1909±1918.
Forster, R., Schubel, A., Breitfeld, D., Kremmer, E., Renner-Muller,
I., Wolf, E., and Lipp, M. (1999). Cell 99, 23±33.
Geijtenbeek, T.B.H., Torensma, R., van Vliet, S.J., van Duijnhoven,
G.C.F., Adema, G.J., van Kooyk, Y., and Figdor, C.G. (2000a). Cell
100, this issue, 575±585.
Geijtenbeek, T.B.H., Kwon, D.S., Torensma, R., van Vliet, S.J., van
Duijnhoven, G.C.F., Middel, J., Cornelissen, I.L.M.H.A., Nottet,
H.S.L.M., KewalRamani, V.N., Littman, D.R., Figdor, C.G., and van
Kooyk, Y. (2000b). Cell 100, this issue, 587±597.
Granelli-Piperno, A., Finkel, V., Delgado, E., and Steinman, R.M.
(1999). Current Biol. 9, 21±29.
